Therapy-related myelodysplastic syndrome with trisomy 1q due to der(1;7) and megakaryoblastic proliferation developing during complete remission of therapy-related acute myeloid leukemia with t(8;21)

Internal Medicine

Volumn 43, Issue 7, 2004, Pages 582-586

  Sakai, Chikara ^a   Matsubayashi, Keiko ^a   Saotome, Takashi ^a   Ishii, Akihiro ^a   Kumagai, Kyoya ^a  

^a CHIBA CANCER CENTER   (Japan)

Author keywords

Alkylating agents; CD41; T cell lymphoma; Topoisomerase II inhibitors

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTARABINE 5' STEARYLPHOSPHATE; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ENOCITABINE; ETOPOSIDE; GYRASE INHIBITOR; MELPHALAN; MERCAPTOPURINE; MITOXANTRONE; PREDNISOLONE; PROCARBAZINE; RANIMUSTINE; VINCRISTINE; VINDESINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CASE REPORT; CELL COUNT; CELL PROLIFERATION; CEREBELLUM TUMOR; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 7; CHROMOSOME TRANSLOCATION 8; FEMALE; HUMAN; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MEGAKARYOBLAST; MYELODYSPLASTIC SYNDROME; T CELL LYMPHOMA; TRISOMY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MYELOCYTIC, ACUTE; LYMPHOMA, T-CELL; MYELODYSPLASTIC SYNDROMES; RISK ASSESSMENT; TRISOMY;

EID: 4444284989     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.43.582     Document Type: Article

References (20)

1. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 86: 3542-3552, 1995.
2. Kantarjian HM, Keating MJ, Walters RS, et al. The association of specific "favorable" cytogenetic abnormalities with secondary leukemia. Cancer 58: 924-927, 1986.
3. Penaux P, Lucidarme D, Lai JL, Bauters F. Favorable cytogenetic abnormalities in secondary leukemia. Cancer 63: 2505-2508, 1989.
4. Quesnel B, Kantarjian H, Bjergaard JP, et al. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): A report on 25 cases and review of the literature. J Clin Oncol 11: 2370-2379, 1993.
5. Pedersen-Bjergaard J, Andersen MK, Johansson B. Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors. J Clin Oncol 16: 1897-1898, 1998.
6. Takagi T, Sampi K, Sawada U, Sakai C, Oguro M. A comparative study of CHOP versus MEVP (mitoxantrone, etoposide, vindesine, prednisolone) therapy for intermediate-grade and high-grade non-Hodgkin's lymphoma: A prospective randomized study. Internat J Hematol 57: 67-71, 1993.
7. Brunning RD, Bennett J, Matutes E, et al. Acute Megakaryoblastic Leukaemia. in: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Jaffe ES, Harris NL, Stein H, Vardiman JW, Eds. IARC Press, Lyon, 2001: 99-101.
8. Sakai C, Ishii A, Sato M, Ito M, Inada Y. Increase in the number of patients with hematological disease receiving long-term platelet transfusion at an outpatient clinic. Jpn J Transf Med 49: 549-552, 2003 (in Japanese, Abstract in English).
9. Pedersen-Bjergaard J, Daugaard G, Hansen SW, Philip P, Larsen SO, Rorth M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 338: 359-363, 1991.
10. Geraedts JPM, den Ottolander GJ, Ploem JE, Muntinghe OG. An identical translocation between chromosome 1 and 7 in three patients with myelofibrosis and myeloid metaplasia. Br J Haematol 44: 569-575, 1980.
11. Mecucci C, Ghione F, Tricot G, Van Den Berghe H. Combined trisomy 1q and monosomy 7q due to translocation 1;7 in myelodysplastic syndromes. Cancer Genet Cytogenet 18: 193-197, 1985.
12. Scheres JMJC, Hustinx TWJ, Geraedts JPM, Leeksma CHW, Meltzer PS. Translocation 1;7 in hematologic disorders: A brief review of 22 cases. Cancer Genet Cytogenet 18: 207-213, 1985.
13. Morrison-DeLap SJ, Kuffel DG, Dewald GW, Letendre L. Unbalanced 1;7 translocation and therapy-induced hematologic disorders: A possible relationship. Am J Hematol 21: 39-47, 1986.
14. Andersen MK, Pedersen-Bjergaard J. Increased frequency of dicentric chromosomes in therapy-related MDS and AML compared to de novo disease is significantly related to previous treatment with alkylating agents and suggests a specific susceptibility to chromosome breakage at the centromere. Leukemia 14: 105-111, 2000.
15. Horiike S, Taniwaki M, Misawa S, et al. The unbalanced 1;7 translocation in de novo myelodysplastic syndrome and its clinical implication. Cancer 65: 1350-1354, 1990.
16. Fonatsch C, Haase D, Freund M, Bartels H, Tesch H. Partial trisomy 1q: A nonrandom primary chromosomal abnormality in myelodysplastic syndromes? Cancer Genet Cytogenet 56: 243-253, 1991.
17. Pedersen B, Norgaard JM, Pedersen BB, Clausen N, Rasmussen IH, Thorling K. Many unbalanced translocations show duplication of a translocation participant. Clinical and cytogenetic implications in myeloid hematologic malignancies. Am J Hematol 64: 161-169, 2000.
18. Hamamoto K, Hashimoto-Ninomiya A, Kishimoto Y, et al. Unbalanced 1;7 translocation in myelodysplastic syndrome following treatment of acute myeloblastic leukemia with an 8;21 translocation. Cancer Genet Cytogenet 74: 35-39, 1994.
19. Carroll A, Civin C, Schneider N, et al. The t(1;22)(p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: A pediatric oncology group study. Blood 78: 748-752, 1991.
20. Dastugue N, Lafage-Pochitaloff M, Pages MP, et al. Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Français de Cytogenetique Hematologique (GFCH). Blood 100: 618-626, 2002.